Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 7Colorectal Neoplasms 5Breast Neoplasms 5Prostatic Neoplasms 4COVID-19 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Lung Neoplasms 2Cholangiocarcinoma 2Untreated Resectable Pancreatic Adenocarcinoma 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Peripheral Nervous System Diseases 1Pancreatic Cancer Resectable 1Neoplasm, Residual 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Klatskin Tumor 1Hypoxia 1Hematologic Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 31Gemcitabine 26Nivolumab 20atezolizumab 16Cisplatin 15avelumab 14Carboplatin 12Docetaxel 10enfortumab vedotin 8Magnetic Resonance Spectroscopy 8durvalumab 7Specimen Handling 7Paclitaxel 7Ipilimumab 6toripalimab 5pemigatinib 5cabozantinib 5vinflunine 4sacituzumab govitecan 4Taxes 4Pemetrexed 4tislelizumab 3cabazitaxel 3Standard of Care 3Mitomycin 3Injections 3Everolimus 3Albumin-Bound Paclitaxel 3sapanisertib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Transitional Cell × Hydroxychloroquine × Clear all
NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2 Recruiting
94 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡